U.S. market Closed. Opens in 11 hours 31 minutes

BHC | Bausch Health Companies Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range 7.39 - 8.11
52 Week Range 3.96 - 11.46
Beta 0.79
Implied Volatility 116.03%
IV Rank 45.90%
Day's Volume 7,825,969
Average Volume 3,774,366
Shares Outstanding 367,102,870
Market Cap 2,944,165,017
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 1994-03-29
Valuation
Profitability
Growth
Health
P/E Ratio -6.22
Forward P/E Ratio N/A
EPS -1.29
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 20,270
Country Canada
Website BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
BHC's peers: VTRS, CTLT, MNK, TLRY, ZTS, PETQ, EBS, NBIX, TEVA, HLN, TAK, SHPH, LFCR, LSDI
*Chart delayed
Analyzing fundamentals for BHC we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see BHC Fundamentals page.

Watching at BHC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on BHC Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙